Treatment strategies for Boerhaave syndrome: multinational retrospective cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hauge Tobias, Abu Hejleh Aram, Aiolfi Alberto, Berlth Felix, Bonavina Luigi, Brake Linda, Conradi Lena-Christin, D'Journo Xavier Benoit, Edholm David, Elliot Jessie, Eshuis Wietse, Friedrich Nora, Gisbertz Suzanne, Grimminger Peter, Gutschow Christian Alexander, Joglekar Shantanu, Klarenbeek Bastiaan, Klevebro Fredrik, Kooij Cezanne D, Luyer Misha, Milazzo Alfio, Moletta Lucia, Moons Johnny, Moorthy Krishna, Müller-Stich Beat P, Nienhüser Henrik, Nafteux Philippe, Nezi Giulia, Nico Raphael, Neuschütz Kerstin J, Nieuwenhuijzen Grard, Raftery Nicola, Renger Franziska, Rouvelas Ioannis, Ruurda Jelle P, Schneider Marcel A, Polette Stubb Daniela, Todesco Alban, Valmasoni Michele, van Berge Henegouwen Mark I, van Daele Elke, van Hillegersberg Richard, van Hootegem Sander J M, Vanommeslaeghe Hanne, Veziant Julie, Wijnhoven Bas, Vilela João Pedro, Bruns Christiane J, Nilsson Magnus, Schröder Wolfgang
Аннотация
METHODS: A multicentre retrospective analysis of data from 23 participating European tertiary centres was performed. Patients with Boerhaave syndrome treated between January 2019 and December 2023 were eligible for inclusion. The primary endpoint was the length of ICU stay and secondary endpoints included in-hospital mortality, 90-day mortality, and the length of overall hospital stay.
RESULTS: In total, 216 patients were included; 151 were men (70%), the median age was 62 (22-95) years, and 81 (40%) were treated >24 h after the start of symptoms. Seventy (32%) patients were managed endoscopically (group I), 73 (34%) were managed surgically (group II), 67 (31%) were managed using a combination of endoscopy and surgery (group III), and 6 (3%) were managed using other methods (group IV). For patients in groups I-III: the median length of ICU stay was 8 (0-67) days, with no differences between the three groups (P = 0.105); the in-hospital mortality rate and 90-day mortality rate were both 12% (P = 0.490 and P = 0.637, respectively); and the median length of overall hospital stay was 27 (range 1-193) days, with the longest stays observed in patients who received combined treatment (P = 0.032).
CONCLUSION: This study provides a comprehensive overview of the current treatment strategies and outcomes for patients with Boerhaave syndrome in Europe.